Chronic Lymphocytic LeukemiaPhase 4NCT06876649
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Phase 4 study testing Pirtobrutinib in people with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, run by Eli Lilly and Company at 38 sites in 8 countries.
Trial summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- What is being tested?
- Pirtobrutinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 787 participants
- Where
- 38 sitesin 8 countries
- Study dates
- 20 May 2025to Dec 2032
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Who cannot join
None listed.
Trial locations and contacts
38 sites in 8 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
38 sites in 8 countries
United States20 sites, 20 recruiting
- Not yet recruiting
The Emory Clinic
Atlanta, Georgia, 30322-1013
404-778-3708
Jonathon Cohen
- Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
617-632-5847
Jennifer Brown
- Not yet recruiting
Northwestern University
Chicago, Illinois, 60611-3013
60611-3013
Shuo Ma
- Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210-1063
614-293-3196
Jennifer Woyach
- Recruiting
Duke University Medical Center
Durham, North Carolina, 27710-4000
919-684-8111
Matthew McKinney
- Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
713-792-2860
Michael Wang
- Recruiting
Cayuga Cancer Center
Ithaca, New York, 14850
607-272-5414
Cynthia Davis
- Not yet recruiting
Cancer Specialists, LLC
Jacksonville, Florida, 32256
Ayed Ayed
- Recruiting
Northwell Health
Lake Success, New York, 11042-1118
516-734-8959
Steven Allen
- Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136-1002
954-265-6549
Alvaro Alencar
- Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3548
414-805-4600
Nirav Shah
- Recruiting
Tennessee Oncology
Nashville, Tennessee, 37203-2659
615-524-4074
Michael Byrne
- Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10065-6007
646-608-4273
Prioty Islam
- Not yet recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10065-6007
646-608-4273
Prioty Islam
- Not yet recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, 10065-6007
Prioty Islam
- Recruiting
University Of Nebraska Medical Center
Omaha, Nebraska, 69198
402-559-5166
Matthew Lunning
- Recruiting
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104
215-662-3933
Sunita Nasta
- Recruiting
Mayo Clinic- Minnesota
Rochester, Minnesota, 55905
507-284-2511
Yucai Wang
- Recruiting
Florida Cancer Specialists
Sarasota, Florida, 34232-6422
941-377-9993
Manish Patel
- Recruiting
Swedish Cancer Institute
Seattle, Washington, 98104-3588
98104-3588
Swathi Namburi
Japan6 sites, 6 recruiting
- Recruiting
Nagoya Medical Center
Aichi-Ken, 4600001
81120023812
Hirokazu Nagai
- Recruiting
National Cancer Center Hospital
Cho-ku, 104-0045
81120023812
Koji Izutsu
- Recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395
81120023812
Kaname Miyashita
- Recruiting
Tokai University Hospital- Isehara Campus
Isehara, 259-1193
81120023812
Yoshiaki Ogawa
- Recruiting
Tohoku University Hospital
Miyagi-Ken, 9808574
81120023812
Noriko Fukuhara
- Recruiting
Hokkaido University Hospital
Sapporo, 060-8648
81120023812
Daigo Hashimoto
Australia3 sites, 3 recruiting
- Recruiting
Flinders Medical Centre
Adelaide, 5042
+61882044018
Hui-Peng Lee
- Recruiting
Peter MacCallum Cancer Centre
Melbourne, 3000
61396561158
John Seymour
- Recruiting
Linear Clinical Research
Victoria, 3000
61893467600
Chan Cheah
United Kingdom3 sites, 3 recruiting
- Recruiting
St James's University Hospital
Leeds, LS9 7TF
+441132433144
Talha Munir
- Not yet recruiting
Churchill Hospital
Oxford, OX3 7LE
+447728268414
Toby Eyre
- Recruiting
Derriford Hospital
Plymouth, PL6 8DH
+441752431043
David John Lewis
Italy2 sites, 2 recruiting
- Recruiting
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
Bologna, 40138
+39512144042
Pier Luigi Zinzani
- Recruiting
Ospedale San Raffaele
Milan, 20132
+390226434797
Paolo Ghia
Poland2 sites, 2 recruiting
- Recruiting
Pratia MCM Krakow
Krakow, 30727
+48124003200
Wojciech Jurczak
- Recruiting
Instytut Hermatologii I Transfuzjologii
Warsaw, 02776
+48223496334
Ewa Lech-Maranda
France1 site, 1 recruiting
- Recruiting
CHU de Nantes - Hotel Dieu
Nantes, 44093
+33240083271
Thomas Gastinne
South Korea1 site, 1 recruiting
- Recruiting
Seoul National University Hospital
Seoul, 03080
821071243234
Ja Min Byun
About this study
Official title: A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- Being tested
- Pirtobrutinib
- Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PirtobrutinibDrug
Also called LOXO-305, LY3527727
Administered orally.
| Study group | Role | What they receive |
|---|---|---|
| JZ01 Pirtobrutinib | Experimental | Participants receive pirtobrutinib as defined in the originator study (LOXO-BTK-18001/J2N-OX-JZNA).
Pirtobrutinib administered orally. Receives: Drug: Pirtobrutinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with a Grade ≥3 treatment-emergent AEs
Measured: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier
Secondary outcomes (1)
Overall Survival
Overall survival is defined as the time from randomization in a randomized Originator study, or from the first dose in a non-randomized Originator study, until death from any cause.
Measured: Time from randomization in a randomized Originator study, or from the first dose in a non-randomized Originator study, until death from any cause (Up to 93 Months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2025
- Study start20 May 2025
- Primary completionMay 2030 (estimated)
- Study completionDec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Lymphocytic LeukemiaStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 787 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06876649
- Sponsor's protocol ID
- 27202
- Other IDs
- 2024-517760-29-00, J2N-MC-JZNY, J2N-MC-JZ01, J2N-MC-JZ02, J2N-MC-JZ03
- Status last verified
- Feb 2026
- First submitted
- 6 Mar 2025
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
- ClinicalTrials.gov ID
- NCT06876649
- Acronym / sponsor ID
- 27202
- Conditions
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 787 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 20 May 2025 (actual)
- Primary completion
- May 2030 (estimated)
- Study completion
- Dec 2032 (estimated)
- First posted
- 14 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| JZ01 Pirtobrutinib | Experimental | Drug: PirtobrutinibParticipants receive pirtobrutinib as defined in the originator study (LOXO-BTK-18001/J2N-OX-JZNA). Pirtobrutinib administered orally. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PirtobrutinibAlso: LOXO-305, LY3527727Administered orally. | Drug | JZ01 Pirtobrutinib |
Primary outcome
Percentage of Participants with a Grade ≥3 treatment-emergent AEs
Time frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier
1 secondary outcome
Overall Survival
Time frame: Time from randomization in a randomized Originator study, or from the first dose in a non-randomized Originator study, until death from any cause (Up to 93 Months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Chronic Lymphocytic Leukemia
RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 1/2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
B-NHL, B-Non Hodgkin Lymphoma
RecruitingPhase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Active, not recruitingPhase 3
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
38 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Pirtobrutinib in people with Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, run by Eli Lilly and Company at 38 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in United States, Japan, Australia, United Kingdom, Italy and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with a Grade ≥3 treatment-emergent AEs (time frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.